Events
Stay on top of what’s happening at JPM. BioSpace is covering all the key announcements all week.
Twist Bioscience announced a partnership with Astellas Pharma on Monday, seeking to discover antibodies against several targets to hit on curative therapies for hard-to-treat diseases.
Stay on top of what’s happening at JPM. BioSpace is covering all the key announcements all week.
JP Morgan week is shaping up to approximate pre-pandemic attendance levels as executives return to San Francisco after two years of COVID-19-enforced absences.
BioSpace spoke with several leaders to gather their thoughts and predictions for the new year. Here is the first installment of this two-part series.
Madrigal’s NASH drug hits the mark in late-stage trial.
Developed initially to deliver cytotoxic payloads to tumors, antibody therapeutics are evolving to provide new, next-generation conjugates and treat various diseases beyond cancer.
Combinations including Ibrutinib stood out in hard-to-treat hematological cancers at the 64th American Society of Hematology (ASH) annual meeting.
AstraZeneca posted two mid-stage wins at the 2022 San Antonio Breast Cancer Symposium on Thursday, touting the efficacy of capivasertib and camizestrant against breast cancer.
Novartis reported Thursday that a Phase III trial of iptacopan met its primary endpoint in paroxysmal nocturnal hemoglobinuria (PNH) - the company’s second win in this indication in as many months.
PRESS RELEASES